Statement of Changes in Beneficial Ownership (4)
July 09 2019 - 4:20PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Davidson David
|
2. Issuer Name
and
Ticker or Trading Symbol
bluebird bio, Inc.
[
BLUE
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director
_____ 10% Owner
__
X
__ Officer (give title below)
_____ Other (specify below)
Chief Medical Officer
|
(Last)
(First)
(Middle)
C/O BLUEBIRD BIO, INC., 60 BINNEY STREET
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
7/5/2019
|
(Street)
CAMBRIDGE, MA 02142
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock
|
7/5/2019
|
|
M
|
|
7330
|
A
|
$50.51
|
38946
|
D
|
|
Common Stock
|
7/5/2019
|
|
M
|
|
330
|
A
|
$5.5004
|
39276
|
D
|
|
Common Stock
|
7/5/2019
|
|
S
(1)
|
|
2828
|
D
|
$128.2762
(2)
|
36448
|
D
|
|
Common Stock
|
7/5/2019
|
|
S
(1)
|
|
832
|
D
|
$129.3168
(3)
|
35616
|
D
|
|
Common Stock
|
7/5/2019
|
|
S
(1)
|
|
3300
|
D
|
$130.0464
(4)
|
32316
|
D
|
|
Common Stock
|
7/5/2019
|
|
S
(1)
|
|
700
|
D
|
$131.7686
(5)
|
31616
|
D
|
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Stock Option (right to buy)
|
$50.51
|
7/5/2019
|
|
M
|
|
|
7330
|
(6)
|
3/1/2026
|
Common Stock
|
7330
|
$0.00
|
19745
|
D
|
|
Stock Option (right to buy)
|
$5.5004
|
7/5/2019
|
|
M
|
|
|
330
|
(7)
|
1/16/2023
|
Common Stock
|
330
|
$0.00
|
0
|
D
|
|
Explanation of Responses:
|
(1)
|
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2019.
|
(2)
|
The range in prices for the transaction reported on this line was $127.92 to $128.89. The average weighted price was $128.2762. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
|
(3)
|
The range in prices for the transaction reported on this line was $128.93 to $129.83. The average weighted price was $129.3168. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
|
(4)
|
The range in prices for the transaction reported on this line was $129.94 to $130.91. The average weighted price was $130.0464. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
|
(5)
|
The range in prices for the transaction reported on this line was $131.26 to $132.23. The average weighted price was $131.7686. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
|
(6)
|
This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 4, 2017 and in 36 equal monthly installments thereafter.
|
(7)
|
This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013 and April 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014 and April 1, 2014, respectively, with the remainder of the shares vesting in equal monthly installments over the following three years.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Davidson David
C/O BLUEBIRD BIO, INC.
60 BINNEY STREET
CAMBRIDGE, MA 02142
|
|
|
Chief Medical Officer
|
|
Signatures
|
/s/ Jason F. Cole, Attorney-in-Fact
|
|
7/9/2019
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Mar 2024 to Apr 2024
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Apr 2023 to Apr 2024